[go: up one dir, main page]

TR200000662T2 - Doğal-olmayan seçici agonistler kullanılarak kemik hacminin arttırılması yöntemi. - Google Patents

Doğal-olmayan seçici agonistler kullanılarak kemik hacminin arttırılması yöntemi.

Info

Publication number
TR200000662T2
TR200000662T2 TR2000/00662T TR200000662T TR200000662T2 TR 200000662 T2 TR200000662 T2 TR 200000662T2 TR 2000/00662 T TR2000/00662 T TR 2000/00662T TR 200000662 T TR200000662 T TR 200000662T TR 200000662 T2 TR200000662 T2 TR 200000662T2
Authority
TR
Turkey
Prior art keywords
unnatural
bone volume
increasing bone
selective agonists
agonist
Prior art date
Application number
TR2000/00662T
Other languages
English (en)
Inventor
Richard Hartke James
Walden Lundy Mark
Anthony Delong Mitchell
Original Assignee
The Procter & Gamble Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Procter & Gamble Company filed Critical The Procter & Gamble Company
Publication of TR200000662T2 publication Critical patent/TR200000662T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Mevcut bulus kemik hacmini arttirmanin yeni yöntemleri ile ilgilidir, bir dogal olmayan seçici FP agonistinin bu tür bir tedaviye ihtiyaci olan bir hastaya uygulanmasindan olusur. Bu bulus ayrica kemik düzensizliklerinin tedavisi veya önlenmesinin bir yöntemi ile ilgilidir, bir dogal olmayan seçici FP agonistinin bu tür bir tedaviye ihtiyaci olan bir hastaya uygulanmasindan olusur.
TR2000/00662T 1997-09-09 1998-09-04 Doğal-olmayan seçici agonistler kullanılarak kemik hacminin arttırılması yöntemi. TR200000662T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5830697P 1997-09-09 1997-09-09

Publications (1)

Publication Number Publication Date
TR200000662T2 true TR200000662T2 (tr) 2000-07-21

Family

ID=22015996

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/00662T TR200000662T2 (tr) 1997-09-09 1998-09-04 Doğal-olmayan seçici agonistler kullanılarak kemik hacminin arttırılması yöntemi.

Country Status (20)

Country Link
US (1) US6156799A (tr)
EP (1) EP1045694A1 (tr)
JP (1) JP2001515864A (tr)
KR (1) KR20010023840A (tr)
CN (1) CN1269721A (tr)
AR (1) AR013479A1 (tr)
AU (1) AU739275B2 (tr)
BR (1) BR9811780A (tr)
CA (1) CA2303800A1 (tr)
CO (1) CO4980882A1 (tr)
HU (1) HUP0004581A2 (tr)
ID (1) ID24827A (tr)
IL (1) IL134760A0 (tr)
NO (1) NO20001171L (tr)
PE (1) PE119099A1 (tr)
PL (1) PL339288A1 (tr)
SK (1) SK3412000A3 (tr)
TR (1) TR200000662T2 (tr)
WO (1) WO1999012551A1 (tr)
ZA (1) ZA988228B (tr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01008956A (es) * 1999-03-05 2002-04-24 Procter & Gamble Analogos de protaglandinas selectivas de fp no saturadas de c16.
WO2000051616A1 (en) * 1999-03-05 2000-09-08 The Procter & Gamble Company Method of increasing bone volume using non-naturally-occurring selective fp agonist and dito ep1 agonist prostaglandin derivatives
JP4834224B2 (ja) 1999-03-05 2011-12-14 デューク ユニバーシティ Ｃ１６不飽和ｆｐ−選択的プロスタグランジン類縁体
NZ513828A (en) * 1999-03-05 2001-09-28 Procter & Gamble Method of increasing bone volume using non-naturally-occurring EP1 selective agonists
CA2303060A1 (en) * 1999-04-14 2000-10-14 United States Gear Corporation Towed vehicle brake controller
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US7545964B2 (en) 2000-08-29 2009-06-09 Imaging Therapeutics, Inc. Methods and devices for quantitative analysis of x-ray images
US6904123B2 (en) 2000-08-29 2005-06-07 Imaging Therapeutics, Inc. Methods and devices for quantitative analysis of x-ray images
US7467892B2 (en) 2000-08-29 2008-12-23 Imaging Therapeutics, Inc. Calibration devices and methods of use thereof
US7660453B2 (en) 2000-10-11 2010-02-09 Imaging Therapeutics, Inc. Methods and devices for analysis of x-ray images
US8639009B2 (en) 2000-10-11 2014-01-28 Imatx, Inc. Methods and devices for evaluating and treating a bone condition based on x-ray image analysis
ATE440536T1 (de) 2001-05-25 2009-09-15 Imaging Therapeutics Inc Verfahren zur diagnose, behandlung und prävention von knochenverlust
EP1417975B1 (en) * 2001-07-23 2011-03-02 Ono Pharmaceutical Co., Ltd. Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient
ES2360604T3 (es) * 2001-07-23 2011-06-07 Ono Pharmaceutical Co., Ltd. Remedios para enfermedades con pérdida de masa osea que tienen como ingrediente activo agonistas de ep4.
WO2003072020A2 (en) * 2002-02-07 2003-09-04 Rutgers, The State University Of New Jersey Therapeutical polyanhydride compounds for drug delivery
US8965075B2 (en) 2002-09-16 2015-02-24 Imatx, Inc. System and method for predicting future fractures
US7840247B2 (en) 2002-09-16 2010-11-23 Imatx, Inc. Methods of predicting musculoskeletal disease
US7664298B2 (en) 2003-03-25 2010-02-16 Imaging Therapeutics, Inc. Methods for the compensation of imaging technique in the processing of radiographic images
US8290564B2 (en) 2003-09-19 2012-10-16 Imatx, Inc. Method for bone structure prognosis and simulated bone remodeling
US20080058613A1 (en) * 2003-09-19 2008-03-06 Imaging Therapeutics, Inc. Method and System for Providing Fracture/No Fracture Classification
AU2004274003A1 (en) * 2003-09-19 2005-03-31 Imaging Therapeutics, Inc. Method for bone structure prognosis and simulated bone remodeling
WO2006034018A2 (en) 2004-09-16 2006-03-30 Imaging Therapeutics, Inc. System and method of predicting future fractures
US8939917B2 (en) 2009-02-13 2015-01-27 Imatx, Inc. Methods and devices for quantitative analysis of bone and cartilage

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4621100A (en) * 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
WO1993015767A1 (en) * 1992-02-05 1993-08-19 Merck & Co., Inc. Implant therapy for bone growth stimulation
US5310759A (en) * 1992-08-12 1994-05-10 Bockman Richard S Methods of protecting and preserving connective and support tissues
US5409911A (en) * 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
US5747660A (en) * 1995-11-06 1998-05-05 The University Of Colorado Nucleic acid encoding prostaglandin F2α receptor regulatory protein
US5703108A (en) * 1996-02-28 1997-12-30 Pfizer Inc. Bone deposition by certain prostaglandin agonists

Also Published As

Publication number Publication date
PL339288A1 (en) 2000-12-04
CN1269721A (zh) 2000-10-11
AR013479A1 (es) 2000-12-27
US6156799A (en) 2000-12-05
NO20001171L (no) 2000-05-09
SK3412000A3 (en) 2000-12-11
CA2303800A1 (en) 1999-03-18
JP2001515864A (ja) 2001-09-25
BR9811780A (pt) 2000-09-12
PE119099A1 (es) 2000-02-03
CO4980882A1 (es) 2000-11-27
AU9219298A (en) 1999-03-29
NO20001171D0 (no) 2000-03-07
ZA988228B (en) 1999-03-09
ID24827A (id) 2000-08-24
KR20010023840A (ko) 2001-03-26
IL134760A0 (en) 2001-04-30
WO1999012551A1 (en) 1999-03-18
HUP0004581A2 (hu) 2001-05-28
EP1045694A1 (en) 2000-10-25
AU739275B2 (en) 2001-10-11

Similar Documents

Publication Publication Date Title
TR200000662T2 (tr) Doğal-olmayan seçici agonistler kullanılarak kemik hacminin arttırılması yöntemi.
TR199902033T2 (tr) Diyabet için sülfonilura-glitazon sinerjik kombinasyonlari.
ATE238307T1 (de) Substituierte porphyrinen
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
EA200000563A1 (ru) Способы лечения женщин в постклимактерическом состоянии с применением ультранизких доз эстрогена
EP0986382A4 (en) RAF KINASE HEMMER
ATE330630T1 (de) Antikoagulierende humanisierte antikörper gegen faktor ix, zur verwendung in der behandlung von thrombose
PT987998E (pt) Descelularizacao de tecidos
ATE336248T1 (de) Verwendung von thiazolidinderivaten als antihyperglykämische mittel
NO982055D0 (no) 2-alkylpyrrolidiner
DE69715861D1 (de) Verwendung von pyridyl-alkan-,pyridiyl alkan- und/oder pyridyl-säuren amiden zur behandlung von tumoren oder für immunsuppression
DK486587A (da) Gen, kodende for humane kolonistimulerende faktorer
ATE228502T1 (de) Substituierte analoge von indol-3-carbinol und von diindolmethan als antiestrogene
PT1083903E (pt) Indenopirrolocarbazoles em ponte
ES2079481T3 (es) Un procedimiento para la determinacion de la actividad funcional de la proteina s o de la proteina c libre en una muestra de plasma.
ATE473294T1 (de) Verfahren und zusammensetzungen zur verwendung von mhc-klasse ii-invariante-kette-polypeptid als rezeptor für makrophagenwanderung-hemmfaktor
NO971341D0 (no) Promoter for reseptor tyrosinkinase TIE
TR200002646T2 (tr) Yeni eprosartan bileşimleri
EP1254260A4 (en) METHODS FOR DIAGNOSING AND TREATING A HEART DISEASE
MXPA99011362A (es) Empleo de 2-mercapto-piridin-n-oxido.
PE20399A1 (es) Muteina ob
ATE288498T1 (de) Methoden zur inhibierung von helicobacter pylori
ATE216386T1 (de) Kv2.1 antagonisten
ATE165594T1 (de) Triarylethylenderivate zur therapeutischen verwendung
ATE40116T1 (de) 1-acyl-3-pyridylmethylguanidine und deren verwendung als antihypertensiva.